At the 44th Annual J.P. Morgan Healthcare Conference in January 2026, AbbVie presented a comprehensive update on its strategic evolution. The company has effectively transitioned from its long-standing reliance on Humira by leveraging robust performance across its immunology, neuroscience, and oncology divisions.
Financial resilience and operational performance Despite one of the most significant patent expirations in pharmaceutical history, AbbVie reported strong financial stability:
-
Growth trajectory: The company absorbed approximately $10 billion in revenue erosion from Humira biosimilars but countered this with $7 billion in net sales growth between 2023 and 2025.
-
Key metrics: Total top-line revenue grew by 8% in 2025, while the core growth platforms surged by nearly 19%.
-
Future investment: R&D spending remained steady at 15% of revenue, totaling roughly $9 billion in 2025 to fuel long-term innovation.
Primary revenue drivers for the next decade
-
Immunology dominance: Successors Skyrizi and Rinvoq are on track to generate combined sales exceeding $41 billion by 2031, as they expand into new indications like lupus and vitiligo.
-
Neuroscience expansion: Currently the fastest-growing segment, the neuroscience portfolio—led by a comprehensive migraine franchise—is projected to surpass $8.1 billion by 2031.
-
Oncology & Business development: The company is aggressively diversifying its pipeline, evidenced by over 40 transactions since 2024, including a major $5.6 billion licensing deal for novel cancer therapies.
By focusing on a diversified portfolio and operational efficiency, AbbVie has established a durable growth profile that extends well into the 2030s, successfully navigating the post-exclusive era of its legacy products.